PPTA Twitter

PlasmaProteins
PlasmaProteins Amy Efantis, President & CEO of @PlasmaProteins is grateful for all plasma donors and plasma collectors. Read more here: bit.ly/2N4ExoU pic.twitter.com/rWLUcZ9COe
4 days ago.
PlasmaProteins
PlasmaProteins “Ultimately, what drives my colleagues on the Board, my company, and the staff at PPTA is a focus on patients...” Karen Etchberger, of @CSLBehring , reflects on her election as Chair of @plasmaproteins Global Board of Directors. bit.ly/2u61VeZ pic.twitter.com/QKhDPwL1e0
4 days ago.

The U.S. Senate will try to move forward shortly on a “motion to proceed” to debate on repeal of the Affordable Care Act

PPTA is concerned that access to therapies and important protections for vulnerable patients with rare diseases will not be included in the Better Care Reconciliation Act (BCRA).  In an effort to end what they consider a failing exchange system, Senate Republicans are trying to garner enough votes to proceed to debate on repeal.

The draft versions of BCRA, with various amendments, would allow changes to the Essential Health Benefits that patients who use plasma protein therapies rely on. These include:

1. Prohibit lifetime and annual caps on coverage
2. Prohibit being denied coverage because of a pre-existing condition
3. Allow dependent children on their parents’ insurance until age 26
4. Limit maximum out of pocket costs for patients

Since access to plasma protein therapies to treat primary immunodeficiencies, alpha-1 antitrypsin deficiency, hereditary angioedema and bleeding disorders, such as hemophilia, is so vital to patient well-being, PPTA is telling Senators to vote NO on the current motion to proceed. The four patient protections must be included in whatever health care legislation moves forward in Congress.

 July 25, 2017

Copyright © 2018 PPTA. All rights reserved. (202) 789-3100